Literature DB >> 20407371

Lyme borreliosis: current issues in diagnosis and management.

Sue O'Connell1.   

Abstract

PURPOSE OF REVIEW: Lyme borreliosis is the most common vector-borne bacterial infection in temperate areas of the northern hemisphere. It has been perceived as difficult to diagnose and treat, but much is now known about its clinical presentations, which largely fall into well defined categories in both adults and children. This review features recent publications on clinical diagnosis and management. RECENT
FINDINGS: The reported incidence of Lyme borreliosis has increased markedly in many countries. Many recent publications have focused on clinical and laboratory aspects of paediatric and adult neuroborreliosis, and there is now strong evidence for the efficacy of oral doxycycline for most presentations of neuroborreliosis. Serological tests have improved significantly. Several studies have confirmed that patients treated for early Lyme borreliosis have good overall long-term outcomes. Studies of patients with persistent symptoms following treatment have not shown evidence for active infection or for sustained benefit from prolonged antibiotic treatment.
SUMMARY: Greater efforts are needed to provide education for prevention and early diagnosis to avoid late complications. Further improvements in diagnostic tests would be welcomed. More research is required to assess the causes and management of post-Lyme symptoms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20407371     DOI: 10.1097/QCO.0b013e32833890e2

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  10 in total

1.  Borrelia burgdorferi Infections in the United States.

Authors:  Warren R Heymann; Dana L Ellis
Journal:  J Clin Aesthet Dermatol       Date:  2012-08

2.  Bacterial heterogeneity is a requirement for host superinfection by the Lyme disease spirochete.

Authors:  Artem S Rogovskyy; Troy Bankhead
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

3.  [Diagnosis and treatment of Lyme arthritis. Recommendations of the Pharmacotherapy Commission of the Deutsche Gesellschaft für Rheumatologie (German Society for Rheumatology)].

Authors:  M Gaubitz; F Dressler; H I Huppertz; A Krause
Journal:  Z Rheumatol       Date:  2014-06       Impact factor: 1.372

4.  Intraarticular corticosteroids in refractory childhood Lyme arthritis.

Authors:  S Nimmrich; I Becker; G Horneff
Journal:  Rheumatol Int       Date:  2014-01-04       Impact factor: 2.631

Review 5.  Outpatient parenteral antimicrobial therapy with ceftriaxone, a review.

Authors:  Christopher J A Duncan; David A Barr; R Andrew Seaton
Journal:  Int J Clin Pharm       Date:  2012-04-17

6.  Misleading presentation of acute Lyme neuroborreliosis.

Authors:  Elizabeth Martha Winter; Philip H Rothbarth; Nathalie M Delfos
Journal:  BMJ Case Rep       Date:  2012-12-06

7.  Detecting Lyme disease using antibody-functionalized single-walled carbon nanotube transistors.

Authors:  Mitchell B Lerner; Jennifer Dailey; Brett R Goldsmith; Dustin Brisson; A T Charlie Johnson
Journal:  Biosens Bioelectron       Date:  2013-02-04       Impact factor: 10.618

8.  Clinical, diagnostic and immunological characteristics of patients with possible neuroborreliosis without intrathecal Ig-synthesis against Borrelia antigen in the cerebrospinal fluid.

Authors:  Magnus Vrethem; Mona Widhe; Jan Ernerudh; Ulf Garpmo; Pia Forsberg
Journal:  Neurol Int       Date:  2011-04-08

9.  Experience of Lyme disease and preferences for precautions: a cross-sectional survey of UK patients.

Authors:  Afrodita Marcu; Julie Barnett; David Uzzell; Konstantina Vasileiou; Susan O'Connell
Journal:  BMC Public Health       Date:  2013-05-16       Impact factor: 3.295

10.  Lyme borreliosis in southern United Kingdom and a case for a new syndrome, chronic arthropod-borne neuropathy.

Authors:  M S Dryden; K Saeed; S Ogborn; P Swales
Journal:  Epidemiol Infect       Date:  2014-05-09       Impact factor: 4.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.